Abstract In the last years several studies have been performed on migraine; however, only few topics have changed the clinical practice. Among these, there are physiopathological insights (e.g., allodynia and gastric stasis) or therapeutical evidences (e.g., topiramate) that become very important in the management of migraine and could clarify the different response to the therapies. The aim of a training school on headache should be to link research to practice without transferring contradictory data. To teach is not only to support notions with simple data: we think that knowledge has to be used according to the condition of the patient and the situation in which the migraineurs live.

Keywords Migraine · Research · Therapy · Teaching

Introduction

Aims of a training school are to support students with update scientific information and to prepare new operators to better face their job. A school must be a link between research and practice. The importance of new data obtained from research depends on their reflections on daily activity.

In the last years several studies has been performed on migraine; however, only few topics have changed the clinical practice. Among these, there are physiopathological insights (e.g., allodynia and gastric stasis) or therapeutical evidences (e.g., topiramate) that become very important in the management of migraine and could clarify the different response to the therapies.

Backgrounds

Cutaneous allodynia (CA) refers to the perception of pain or discomfort in response to non-noxious thermal and mechanical stimuli applied to normal skin [1], and is the clinical manifestation of central sensitization in migraine [2, 3]. CA is more commonly reported in persons with frequent headache, long duration of the disorder and transformed migraine, suggesting that it is the result of repeated sensitization of central pathways over time [4–8]. It has been suggested that central sensitization may be associated with neuronal changes impairing efficacy of triptans when used after 1 h from the onset of migraine attacks [9]. Therefore, the triptans effectively abort migraine attacks in 93% of patients prior to development of allodynia, compared with only 15% in the presence of allodynia [10]. Conversely, the presence of allodynia does not limit the use of intramuscular dihydroergotamine [11]. A more recent study suggested that intravenous administration of ketorolac or naproxen may effectively terminate migraine attacks, even after the onset of allodynia [12]. So, during a migraine attack, the acute use of triptans is not indicated after the beginning of allodynia. A possible alternative is to administer i.v. infusion of ketorolac or naproxen.

Several studies demonstrated that a gastric stasis is associated with migraine attacks. In practice, these
evidences prompt the use of antiemetics before treating migraine patients with NSAID [13, 14]. Nevertheless, it has been suggested that gastroparesis is a feature of the migraine rather than of the attack [15]. Some studies suggested that triptans are effective in reducing migrainous nausea by central mechanism of action [16, 17].

Efficacy of topiramate (TPM) in the prevention of migraine is well demonstrated [18, 19]. Last reports focus their attention on long-term use. Usually, prevention should last for 3–4 months, although recent evidences, as well as clinical experience, suggest the possibility of increased efficacy with use of preventive drugs for longer periods (up to 6–14 months) [20–22]. Also the frequency of adverse events was lower in the open label phase than the double-blind phase. A recent review observed that the clinical benefit appears to be sustained in patients treated with TPM over 1 year and that there was no loss of efficacy over time, even when patients switched from a higher to a lower dose [23]. These evidences let clinicians able to use different patterns of therapy, trying to satisfy the needs of patients with very different dosages and times to treat.

Conclusions

We reported only these few insights from clinical research. A training school of headache must link research to practice and does not have to transfer contradictory data. To teach is not only to support notions with simple data: we think that knowledge has to be used according to the condition of the patient and the situation in which the migraineurs live. Beside this, every teacher has his own exclusive experience provided by intuition that can be a good resort to learn something more than simple information. It is just this intuition that can suggest to the researchers new ideas and new strategies to move in new fields. In this case a school can achieve its real goal: to create a two-way relationship between science and daily practice, creating more efficient “actors” in both fields.

Conflict of interest statement  The authors declare that they have no conflict of interest related to the publication of this article.

References

1. Burstein R, Yarnitsky D, Goor-Aryeh I et al (2000) An association between migraine and cutaneous allodynia. Ann Neurol 47:614–624
2. Winkelstein BA (2004) Mechanism of central sensitization, neuroimmunology and injury biomechanics in persistent pain. Implications for musculoskeletal disorders. J Electromyogr Kinesiol 14:87–93
3. Burstein R, Cutrer MF, Yamitsky D (2000) The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123:1703–1709
4. Lipton RB, Bigal ME, Ashina S et al (2008) Cutaneous allodynia in the migraine population. Ann Neurol 63:148–158
5. Bigal ME, Ashina S, Burstein R et al (2008) Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology 70:1525–1533
6. Cooke L, Eliasziw M, Becker WJ (2007) Cutaneous allodynia in transformed migraine patients. Headache 47:531–539
7. LoPinto C, Young WB, Ashkenazi A (2006) Comparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine. Cephalalgia 26:852–856
8. Tietjen GE, Brandel JA, Peterlin BL et al (2009) Allodynia in migraine: association with comorbid pain conditions. Headache 49:1333–1344
9. Burstein R, Jakubowski M (2004) Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 55:27–36
10. Burstein R, Collins B, Jakubowski M (2004) Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 55:19–26
11. Silberstein SD, Young WB, Hopkins MM et al (2007) Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. Headache 47:878–885
12. Jakubowski M, Levy D, Goor-Aryeh I et al (2005) Terminating migraine with allodynia and ongoing central sensitization using pantoprazol administration of COX1/COX2 inhibitors. Headache 45:850–861
13. Volans GN (1975) The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 2:57–63
14. Tokola RA (1988) The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia 8:139–147
15. Aurora S, Kori S, Barrodale P, Nelsen A et al (2007) Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache 47:1443–1446 (Epub Sept 12 2007)
16. Jakubowski M, Levy D, Kainz V et al (2007) Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience 148:573–583 (Epub 25 Jul 2007)
17. Aurora SK, Kori SH, Barrodale P et al (2006) Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache 46:57–63
18. Silberstein SD, Neto W, Schmitt J et al (2004) Topiramate in migraine prevention: results of a large controlled trial. JAMA 291:965–973
19. Bussone G, Diener HC, Pfeil J et al (2005) Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 59:961–968
20. D’Amico D, Tepper SJ (2008) Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat 4:1–13
21. Diener HC, Agosti R, Allais G, For the TOPMAT-MIG-303 Investigators Group et al (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo controlled trial. Lancet Neurol 6:1054–1062
22. Rapaport A, Mauskop A, Diener HC et al (2006) Long-term migraine prevention with topiramate: open label extension of pivotal trials. Headache 46:1151–1160
23. Naegel S, Oberschlegel M (2010) Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference. Neuropsychiatr Dis Treat 6:17–28